Relationship Between Tumor Incompatibility and Therapeutic Response.
- 1 November 1967
- journal article
- research article
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 126 (2), 402-405
- https://doi.org/10.3181/00379727-126-32459
Abstract
A comparison of the histocompatibility characteristics of sarcoma-180 (S-180), sarcoma-180 resistant to Mercaptopurine (S-180/MP), sarcoma-180 resistant to vitamin B6 deficiency (S-180/B6) and Ehrlich carcinoma (ECA) was carried out by transplantation techniques in 7 strains of mice. S-180/MP and S-180/B6 appeared to be less immunogenic than S-180; ECA was less immunogenic than the 2 S-180 sublines. S-180/MP, S-180/B6, and ECA appeared to have antigenic properties in common with S-180. The therapeutic effects of 6MP [6-mercaptopurine] and KTS [kethoxal-bis-thiosemicarbazone] against S-180/B6 were greater in C57B1/6 than in Swiss HaICR mice. The effects of 6MP and vitamin B6 deficiency against ECA were evident only in Swiss HalCR sensitized to S-180. Thus, in this case, the effectiveness of therapeutic treatments was influenced by the degree of the host response to the tumor.This publication has 5 references indexed in Scilit:
- Antitumor Effects of Kethoxal-Bis(Thiosemicarbazone) and 6-Mercaptopurine in Neonatally Thymeetomized Mice.Experimental Biology and Medicine, 1967
- DEPENDENCE OF REGRESSION OF SARCOMA 180 IN VITAMIN B6-DEFICIENT MICE UPON IMMUNOLOGIC COMPETENCE OF HOST1967
- STRAIN SPECIFICITY OF STIMULATED REGRESSION OF SARCOMA 1801965
- HOST DEFENSE MECHANISMS IN REGRESSION OF SARCOMA 180 IN PYRIDOXINE-DEFICIENT MICE1962
- Development of a Sub-Line of Mouse Sarcoma-180 Capable of Growing in Pyridoxine-Deficient AnimalsNature, 1960